Latest News Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold Tumors-BeOne Dec 11 2025 Latest News Google AI Breakthrough Highlights Silmitasertib (CX-4945) as a Novel Pathway in Cancer Immunotherapy Oct 16 2025 Latest News Senhwa Biosciences’ CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market Sep 16 2025 Media Coverage Senhwa Biosciences Partners with BeOne for Advanced Cancer Treatment Dec 11 2025 Media Coverage Google's AI model identified Silmitasertib (CX-4945) as a potential key to boosting tumor antigen presentation by turning cold tumors to hot ones, a new potential cancer therapy pathway. Oct 16 2025 Media Coverage Senhwa Biosciences Highlights Breakthroughs in Dual First-in-Class Drug Programs at Annual Shareholders' Meeting Today Jun 25 2025 Publications Fibroblast growth receptor 1 is regulated by G-quadruplex in metastatic breast cancer Aug 09 2024 Publications CX-5461 Preferentially Induces Top2α-Dependent DNA Breaks at Ribosomal DNA Loci. Jul 08 2024 Publications Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options Sep 22 2023